Welcome to our dedicated page for Intelligent Bio Solutions news (Ticker: INBS), a resource for investors and traders seeking the latest updates and insights on Intelligent Bio Solutions stock.
Intelligent Bio Solutions Inc. develops medical technology for rapid, non-invasive testing, centered on fingerprint sweat drug screening. Its updates commonly cover the Intelligent Fingerprinting Drug Screening System, Drug Screening Cartridges, DSR-Plus reader, lateral-flow test strip manufacturing, and the reader-and-consumable sales model used in workplace testing markets outside the United States.
Company news also focuses on clinical and regulatory work supporting an FDA 510(k) pathway for codeine detection, cybersecurity and validation testing tied to the system, European patent protection for fingerprint chemical analysis, manufacturing scale-up for readers and cartridges, customer deployments in the United Kingdom, and periodic revenue reports by product category.
Intelligent Bio Solutions (Nasdaq: INBS) expects preliminary unaudited fiscal Q2 2026 revenue to rise about 48% YoY, and fiscal H1 2026 total revenue to be approximately $2.01 million (up 36% YoY).
Reader sales are expected to increase ~104% YoY in Q2 while cartridge sales are up ~33% Q2 / 38% H1, with accessories/training also growing. Results are preliminary and subject to quarter-end close and Form 10-Q filing during the week of Feb 9, 2026.
Intelligent Bio Solutions (Nasdaq: INBS) initiated clinical studies on Jan 28, 2026 to support an FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System targeting codeine detection.
The first cohort (40 adults) will use the DSR-Plus reader and fingerprint cartridges, include LC-MS/MS confirmation and predicate-device comparisons; full data analysis is expected by end of March 2026 for incorporation into the 510(k) package.
Intelligent Bio Solutions (Nasdaq: INBS) closed a private placement priced at-the-market, selling 2,298,850 common shares (or pre-funded warrants) plus Series K-1 and K-2 warrants to purchase up to 2,298,850 shares each, for combined gross proceeds of approximately $10.0 million before fees.
The common shares (or pre-funded warrants) and associated warrants were sold at $4.35 per unit; the warrants have an exercise price of $4.10, are exercisable immediately, and will have a five-year term following effectiveness of a registration statement. Proceeds are intended for working capital, general corporate purposes and to fund a 510(k) FDA submission. The company agreed to file a resale registration within 10 days and use best efforts to have it declared effective within 45 days.
Intelligent Bio Solutions (Nasdaq: INBS) entered a private placement to raise approximately $10.0 million in gross proceeds by selling 2,298,850 common shares (or pre-funded warrants) and issuing Series K-1 and K-2 warrants exercisable to purchase up to an additional 2,298,850 shares each at a $4.10 exercise price.
The securities are being sold at a combined purchase price of $4.35 per share (or pre-funded warrant) plus associated warrants, with closing expected on or about January 2, 2026. Ladenburg Thalmann is the exclusive placement agent. Proceeds are intended for working capital and general corporate purposes. The company will file a resale registration statement within 10 calendar days and aims for effectiveness no later than 45 days after the agreement.
Intelligent Bio Solutions (Nasdaq: INBS) announced a strategic manufacturing partnership with Syrma Johari MedTech to scale production of its Intelligent Fingerprinting Drug Screening Reader ahead of planned U.S. market entry in 2026.
The collaboration is expected to deliver >40% annual production cost savings, an ~20 percentage‑point improvement in gross margin versus the prior arrangement, and ~4x current manufacturing capacity through Syrma Johari’s 14 facilities and 1.1M+ sq ft footprint. Syrma Johari holds ISO 13485, MDSAP, FDA, TUV SUD, and GMP certifications to support global regulatory needs.
Intelligent Bio Solutions (Nasdaq: INBS) announced a non-exclusive strategic alliance with Vlepis on Dec 18, 2025 to collaborate on R&D, distribution, and regulatory work for non-invasive testing and wearable patch technologies.
The partnership aims to extend INBS’ Intelligent Fingerprinting and SMARTOX SmarTest Patch into consumer health monitoring, leveraging Vlepis’ wearable sensors and cloud/mobile connectivity to accelerate international commercialization and broaden revenue opportunities.
Intelligent Bio Solutions (Nasdaq: INBS) will effect a 1‑for‑10 reverse stock split at 11:59 PM ET on December 15, 2025, with split‑adjusted trading resuming on Nasdaq at the open on December 16, 2025 under the symbol INBS and new CUSIP 36151G709.
The split was approved by stockholders on October 16, 2025; every 10 shares issued and outstanding will be combined into one share and outstanding equity awards and warrants will be proportionately adjusted. No fractional shares will be issued; holders entitled to fractions will receive a cash payment in lieu of a fractional share. Par value remains $0.01 and authorized shares remain at 100,000,000. Immediately after the reverse split, approximately 959,533 shares will be issued and outstanding.
Intelligent Bio Solutions (NASDAQ: INBS) announced management will participate in Noble Capital Markets’ 21st Annual Emerging Growth Equity Conference on December 2–3, 2025 in Boca Raton, Florida.
The company will present on Wednesday, December 3, 2025 at 11:00 a.m. ET in Presentation Room 2 at Florida Atlantic University. A webcast recording will be available the following day on the company investor relations site, Noble’s website, and Channelchek for 90 days.
Investors may register with discount code INBSNOBLECON. To schedule one-on-one meetings or request more information, contact a Noble Capital Markets representative or email KCSA Strategic Communications at INBS@ksca.com.
Intelligent Bio Solutions (Nasdaq: INBS) reported fiscal 2026 first quarter results for the period ended September 30, 2025, delivering record quarterly revenue of $1,111,797, up 32% sequentially and 28% year‑over‑year. Cartridge consumable sales totaled $640,300, representing 57.59% of revenue. Gross profit margin improved by 690 basis points to 46.6%, attributed to operational efficiency and a higher mix of cartridge sales. The company added 33 net new customer accounts (total active accounts: 492 across 24+ countries), secured a multi‑site contract in London covering 4,400 staff, launched the SmarTest Patch, and signed a global distribution agreement with SMARTOX for markets outside the U.S. and Canada.
Management highlighted consumable‑led recurring revenue momentum and margin expansion while advancing toward planned FDA clearance and U.S. market entry.
Intelligent Bio Solutions (NASDAQ: INBS) reported preliminary, unaudited fiscal Q1 2026 revenue of over $1.0 million, a record for the company, representing approximately +32% sequential and +28% year‑over‑year growth for the quarter ended September 30, 2025.
Revenue strength was driven by new customer accounts and higher product demand: cartridge revenue +43% YoY and reader revenue +23% YoY. This marks the company’s third consecutive quarter of revenue growth and reflects an increasing share of higher‑margin consumables in the sales mix.
Results are preliminary and subject to adjustment; final Q1 2026 financials will be filed on Form 10‑Q during the week commencing November 10, 2025.